Provided by Tiger Trade Technology Pte. Ltd.

Jupiter Neurosciences

2.44
-0.1400-5.43%
Volume:16.80K
Turnover:42.27K
Market Cap:3.22M
PE:-0.13
High:2.61
Open:2.51
Low:2.35
Close:2.58
52wk High:135.75
52wk Low:2.35
Shares:1.32M
Float Shares:1.10M
Volume Ratio:0.41
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.5676
EPS(LYR):-18.7500
ROE:-1888.70%
ROA:-159.56%
PB:-8.79
PE(LYR):-0.13

Loading ...

Jupiter Neurosciences Sells 11,470,000 Shares to Yorkville for About $3.6 Million in Unregistered Offering

Reuters
·
Jul 29

Jupiter Neurosciences Held Annual Shareholder Meeting, with 59% of Shares Represented

Reuters
·
Jul 27

Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences

TIPRANKS
·
Jul 23

Jupiter Neurosciences Director Andrew Jon Cutler Files Initial Beneficial Ownership Statement

Reuters
·
Jul 23

Jupiter Neurosciences Licenses ALA-002 for U.S. Development

TIPRANKS
·
Jul 22

Jupiter Neurosciences Stock (JUNS) Jumps on a New License Deal

TIPRANKS
·
Jul 22

Jupiter Neurosciences (nasdaq: Juns) Signs Definitive Agreement for Exclusive U.S. Rights to Ala-002 in Transaction Valued at up to $100 Million

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Royalty of 3% of Net Sales After Third Commercialization Milestone

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences - Deal Valued at up to $100 Mln Including Milestone Payments

THOMSON REUTERS
·
Jul 21

Pharmala Licenses Exclusive US Rights to Ala-002 to Jupiter Neurosciences for up to Us$100 Million

Reuters
·
Jul 21

Pharmala Biotech - to Manufacture Gmp-grade Ala-002 for Jupiter Under Separate Supply Agreement

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Development and Regulatory Milestones up to $23.33 Mln Including $20 Mln for FDA Approval

THOMSON REUTERS
·
Jul 21

Pharmala Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to Ala-002

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Upfront Payment of $3.33 Mln: $1.50 Mln Cash, $1.83 Mln in Jupiter Stock

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - Deal Valued up to $100 Mln Including $3.33 Mln Upfront and Milestones Plus Royalties

THOMSON REUTERS
·
Jul 21

Pharmala Biotech - to Receive 3% Royalty on U.S. Net Sales After Third Milestone

THOMSON REUTERS
·
Jul 21

Jupiter Neurosciences Names Former White House Economic Adviser Tomas Philipson to Board

Reuters
·
Jul 07

Jupiter Neurosciences Strengthens Board with Appointment of DR. Tomas J. Philipson

THOMSON REUTERS
·
Jul 07

Jupiter Neurosciences Appoints Tomas J. Philipson to Board

Reuters
·
Jul 01

Top Premarket Decliners

MT Newswires Live
·
Jun 29